JP2002528412A - 分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンス - Google Patents
分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンスInfo
- Publication number
- JP2002528412A JP2002528412A JP2000578001A JP2000578001A JP2002528412A JP 2002528412 A JP2002528412 A JP 2002528412A JP 2000578001 A JP2000578001 A JP 2000578001A JP 2000578001 A JP2000578001 A JP 2000578001A JP 2002528412 A JP2002528412 A JP 2002528412A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- endoplasmic reticulum
- cells
- reduces
- misfolded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91097—Hexosyltransferases (general) (2.4.1)
- G01N2333/91102—Hexosyltransferases (general) (2.4.1) with definite EC number (2.4.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Biophysics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10580698P | 1998-10-27 | 1998-10-27 | |
| US60/105,806 | 1998-10-27 | ||
| PCT/US1999/025221 WO2000024391A2 (en) | 1998-10-27 | 1999-10-27 | Conductance of improperly folded proteins through the secretory pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002528412A true JP2002528412A (ja) | 2002-09-03 |
| JP2002528412A5 JP2002528412A5 (cg-RX-API-DMAC7.html) | 2006-12-28 |
Family
ID=22307893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578001A Pending JP2002528412A (ja) | 1998-10-27 | 1999-10-27 | 分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6344475B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1126832A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002528412A (cg-RX-API-DMAC7.html) |
| AU (1) | AU775575B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2348529A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000024391A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236300A1 (en) * | 1999-10-27 | 2003-12-25 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20040266883A1 (en) * | 1999-10-27 | 2004-12-30 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20020132770A1 (en) * | 1999-10-27 | 2002-09-19 | Caplan Michael T. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US6867459B2 (en) * | 2001-07-05 | 2005-03-15 | Isonics Corporation | Isotopically pure silicon-on-insulator wafers and method of making same |
| US7119400B2 (en) * | 2001-07-05 | 2006-10-10 | Isonics Corporation | Isotopically pure silicon-on-insulator wafers and method of making same |
| US20040171226A1 (en) * | 2001-07-05 | 2004-09-02 | Burden Stephen J. | Isotopically pure silicon-on-insulator wafers and method of making same |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| FR2876584B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| US8859020B2 (en) | 2005-05-30 | 2014-10-14 | Benny Antony | Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone |
| US10286027B2 (en) | 2005-05-30 | 2019-05-14 | Arjuna Natural Extracts, Ltd. | Sustained release formulations of curcuminoids and method of preparation thereof |
| US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
| US10543277B2 (en) | 2005-05-30 | 2020-01-28 | Arjuna Natural Private Limited | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
| US12053438B2 (en) | 2005-05-30 | 2024-08-06 | Arjuna Natural Private Limited | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
| US9492402B2 (en) | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
| DK1890546T3 (en) | 2005-05-30 | 2019-03-11 | Benny Antony | Process for improving the bioavailability of curcumin |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP2190850A4 (en) * | 2007-07-03 | 2011-03-09 | Univ British Columbia | DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES |
| GB0809360D0 (en) * | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| RU2637101C2 (ru) * | 2016-01-11 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) | Устройство для определения аспирированной дозы аэрозолей |
| CN116240239B (zh) * | 2023-04-18 | 2024-12-27 | 华东师范大学 | 程序可控的蛋白质快速分泌释放系统及其构建方法和应用 |
| CN116476541B (zh) * | 2023-05-16 | 2025-12-02 | 征图新视(江苏)科技股份有限公司 | 一种针对光学膜卷材的高速打标系统 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013768A1 (en) * | 1992-01-06 | 1993-07-22 | Ariad Pharmaceuticals, Inc. | Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents |
| JPH08500596A (ja) * | 1992-08-26 | 1996-01-23 | ジェンザイム・コーポレイション | 嚢胞性線維症の治療方法および治療用医薬組成物 |
| WO1996036334A1 (en) * | 1995-05-19 | 1996-11-21 | University Of East Anglia | Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| JPH09501922A (ja) * | 1993-08-26 | 1997-02-25 | ナショナル リサーチ カウンシル オブ カナダ | タンパク質が関与する異常性の検出と治療および分泌タンパク質の生産を増加するための組成物と方法 |
| JPH10501130A (ja) * | 1994-05-26 | 1998-02-03 | カイロン コーポレイション | C型肝炎ウイルスアシアロ糖タンパク質 |
| JPH10508575A (ja) * | 1994-08-30 | 1998-08-25 | ユニバーシティ オブ ダンディー | アポトーシス誘導剤及び治療法における該誘導剤の適用 |
| WO1998037878A1 (en) * | 1997-02-27 | 1998-09-03 | Genzyme Corporation | Methods and compositions for treating cystic fibrosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8704089D0 (en) | 1987-02-21 | 1987-03-25 | Fisons Plc | Method of treatment |
| US5384128A (en) | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6015828A (en) | 1996-05-31 | 2000-01-18 | Cuppoletti; John | Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases |
-
1999
- 1999-10-27 AU AU12370/00A patent/AU775575B2/en not_active Expired
- 1999-10-27 US US09/427,696 patent/US6344475B1/en not_active Expired - Lifetime
- 1999-10-27 JP JP2000578001A patent/JP2002528412A/ja active Pending
- 1999-10-27 EP EP99970919A patent/EP1126832A2/en not_active Ceased
- 1999-10-27 WO PCT/US1999/025221 patent/WO2000024391A2/en not_active Ceased
- 1999-10-27 CA CA002348529A patent/CA2348529A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013768A1 (en) * | 1992-01-06 | 1993-07-22 | Ariad Pharmaceuticals, Inc. | Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents |
| JPH08500596A (ja) * | 1992-08-26 | 1996-01-23 | ジェンザイム・コーポレイション | 嚢胞性線維症の治療方法および治療用医薬組成物 |
| JPH09501922A (ja) * | 1993-08-26 | 1997-02-25 | ナショナル リサーチ カウンシル オブ カナダ | タンパク質が関与する異常性の検出と治療および分泌タンパク質の生産を増加するための組成物と方法 |
| JPH10501130A (ja) * | 1994-05-26 | 1998-02-03 | カイロン コーポレイション | C型肝炎ウイルスアシアロ糖タンパク質 |
| JPH10508575A (ja) * | 1994-08-30 | 1998-08-25 | ユニバーシティ オブ ダンディー | アポトーシス誘導剤及び治療法における該誘導剤の適用 |
| WO1996036334A1 (en) * | 1995-05-19 | 1996-11-21 | University Of East Anglia | Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| WO1998037878A1 (en) * | 1997-02-27 | 1998-09-03 | Genzyme Corporation | Methods and compositions for treating cystic fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2348529A1 (en) | 2000-05-04 |
| AU775575B2 (en) | 2004-08-05 |
| AU1237000A (en) | 2000-05-15 |
| EP1126832A2 (en) | 2001-08-29 |
| WO2000024391A3 (en) | 2000-11-30 |
| WO2000024391A2 (en) | 2000-05-04 |
| US6344475B1 (en) | 2002-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6344475B1 (en) | Conductance of improperly folded proteins through the secretory pathway | |
| US8058314B2 (en) | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | |
| Saez et al. | cAMP delays disappearance of gap junctions between pairs of rat hepatocytes in primary culture | |
| CN100374158C (zh) | 降低细胞atp水平的药剂在制备药物中的应用 | |
| Namkung et al. | CFTR-adenylyl cyclase I association responsible for UTP activation of CFTR in well-differentiated primary human bronchial cell cultures | |
| Koval | Sharing signals: connecting lung epithelial cells with gap junction channels | |
| Clancy et al. | Adenosine and its nucleotides activate wild-type and R117H CFTR through an A2Breceptor-coupled pathway | |
| US8138158B2 (en) | Compositions and methods for therapy for diseases characterized by defective chloride transport | |
| JP6253596B2 (ja) | アシル補酵素a:リゾカルジオリピン・アシル基転移酵素1(alcat1)の発現、機能または活性の阻害物質を同定する方法 | |
| US20020132770A1 (en) | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | |
| Wierdl et al. | Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance | |
| US5643883A (en) | Glucose-6-phosphate uptake inhibitors and novel uses thereof | |
| US20030236300A1 (en) | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | |
| de Tilques et al. | Decreasing cytosolic translation is beneficial to yeast and human Tafazzin-deficient cells | |
| de Taffin de Tilques et al. | Overexpression of mitochondrial oxodicarboxylate carrier (ODC1) preserves oxidative phosphorylation in a yeast model of Barth syndrome | |
| US20040266883A1 (en) | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | |
| Chaudary et al. | Transport characteristics of HL-1 cells: a new model for the study of adenosine physiology in cardiomyocytes | |
| Johnson et al. | Polyamines alter intestinal glucose transport | |
| US7741310B2 (en) | Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis | |
| Kaufmann et al. | The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism | |
| Freeze et al. | Biochemical and genetic analysis of an antigenic determinant found on N‐linked oligosaccharides in Dictyostelium | |
| US20230293530A1 (en) | Agents for sensitizing solid tumors to treatment | |
| Polunovsky et al. | Cell fusion to study nuclear-cytoplasmic interactions in endothelial cell apoptosis | |
| EP1556505B1 (en) | Modulation of s6 kinase activity for the treatment of obestiy | |
| Moore et al. | Methylation of erythrocyte membrane phospholipids in patients with myotonic and Duchenne muscular dystrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061027 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100405 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20100405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100405 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100405 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100803 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110104 |